Solid Biosciences (SLDB) Operating Leases (2019 - 2024)
Historic Operating Leases for Solid Biosciences (SLDB) over the last 6 years, with Q3 2024 value amounting to $21.6 million.
- Solid Biosciences' Operating Leases fell 666.7% to $21.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $21.6 million, marking a year-over-year decrease of 666.7%. This contributed to the annual value of $22.7 million for FY2023, which is 647.47% down from last year.
- Latest data reveals that Solid Biosciences reported Operating Leases of $21.6 million as of Q3 2024, which was down 666.7% from $22.1 million recorded in Q2 2024.
- Solid Biosciences' Operating Leases' 5-year high stood at $24.5 million during Q2 2022, with a 5-year trough of $70000.0 in Q1 2022.
- Its 5-year average for Operating Leases is $13.1 million, with a median of $21.6 million in 2024.
- Its Operating Leases has fluctuated over the past 5 years, first tumbled by 9646.46% in 2022, then skyrocketed by 3406000.0% in 2023.
- Quarter analysis of 5 years shows Solid Biosciences' Operating Leases stood at $2.4 million in 2020, then crashed by 88.63% to $275000.0 in 2021, then surged by 8728.73% to $24.3 million in 2022, then fell by 6.47% to $22.7 million in 2023, then decreased by 4.69% to $21.6 million in 2024.
- Its Operating Leases stands at $21.6 million for Q3 2024, versus $22.1 million for Q2 2024 and $22.5 million for Q1 2024.